Travere Therapeutics Stock Today
| TVTX Stock | USD 5.26 0.13 2.41% |
Performance0 of 100
| Odds Of DistressOver 85
|
Travere Therapeutics is trading at 5.26 as of the 28th of April 2024; that is -2.41 percent decrease since the beginning of the trading day. The stock's open price was 5.39. Travere Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Travere Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of February 2024 and ending today, the 28th of April 2024. Click here to learn more.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. The company has 76.11 M outstanding shares of which 11.8 M shares are at this time shorted by private and institutional investors with about 9.43 trading days to cover. More on Travere Therapeutics
Moving together with Travere Stock
| 0.71 | DMAC | DiaMedica Therapeutics Financial Report 20th of May 2024 | PairCorr |
| 0.73 | VAXX | Vaxxinity Financial Report 14th of May 2024 | PairCorr |
Moving against Travere Stock
| 0.75 | VERU | Veru Inc Financial Report 9th of May 2024 | PairCorr |
| 0.68 | YS | YS Biopharma | PairCorr |
| 0.64 | DOMH | Dominari Holdings | PairCorr |
Follow Valuation Odds of Bankruptcy
Financial Report 2nd of May 2024
Travere Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Travere Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Travere Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Eric Dube |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Travere Therapeutics (TVTX) is traded on NASDAQ Exchange in USA. It is located in 3611 Valley Centre Drive, San Diego, CA, United States, 92130 and employs 380 people. Travere Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 400.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Travere Therapeutics's market, we take the total number of its shares issued and multiply it by Travere Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Travere Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 76.11 M outstanding shares of which 11.8 M shares are at this time shorted by private and institutional investors with about 9.43 trading days to cover.
Travere Therapeutics currently holds about 553.17 M in cash with (280.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.65, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Travere Therapeutics Probability Of Bankruptcy
Ownership AllocationTravere Therapeutics maintains a total of 76.11 Million outstanding shares. The majority of Travere Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Travere Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Travere Therapeutics. Please pay attention to any change in the institutional holdings of Travere Therapeutics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Travere Ownership Details
Travere Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Travere Therapeutics jumping above the current price in 90 days from now is about 99.0%. The Travere Therapeutics probability density function shows the probability of Travere Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Travere Therapeutics has a beta of 0.0657. This usually implies as returns on the market go up, Travere Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Travere Therapeutics will be expected to be much smaller as well. Additionally, travere Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Travere Therapeutics to move above the current price in 90 days from now is about 99.0 (This Travere Therapeutics probability density function shows the probability of Travere Stock to fall within a particular range of prices over 90 days) .
Travere Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Travere Therapeutics market risk premium is the additional return an investor will receive from holding Travere Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Travere Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Travere Therapeutics' alpha and beta are two of the key measurements used to evaluate Travere Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (0.84) | |||
| Total Risk Alpha | (1.29) | |||
| Treynor Ratio | (12.74) |
Travere Stock Against Markets
Picking the right benchmark for Travere Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Travere Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Travere Therapeutics is critical whether you are bullish or bearish towards Travere Therapeutics at a given time. Please also check how Travere Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Travere Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Travere Therapeutics Corporate Management
Elected by the shareholders, the Travere Therapeutics' board of directors comprises two types of representatives: Travere Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Travere. The board's role is to monitor Travere Therapeutics' management team and ensure that shareholders' interests are well served. Travere Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Travere Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth JD | General VP | Profile | |
| Elizabeth Reed | General VP | Profile | |
| William Rote | Senior Development | Profile | |
| CFA CFA | Chief Officer | Profile | |
| Angela Giannantonio | Senior Resources | Profile | |
| Jula MD | Chief Officer | Profile | |
| Casey Logan | Chief Officer | Profile |
How to buy Travere Stock?
Before investing in Travere Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Travere Therapeutics. To buy Travere Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Travere Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Travere Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Travere Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Travere Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Travere Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.
Already Invested in Travere Therapeutics?
The danger of trading Travere Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Travere Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Travere Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Travere Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Travere Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Travere Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Travere Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Travere Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Travere Stock analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Travere Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Travere Therapeutics. If investors know Travere will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Travere Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Travere Therapeutics is measured differently than its book value, which is the value of Travere that is recorded on the company's balance sheet. Investors also form their own opinion of Travere Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Travere Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Travere Therapeutics' market value can be influenced by many factors that don't directly affect Travere Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Travere Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Travere Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Travere Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.